Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
10 Results for "
shunt
" in MedChemExpress (MCE) Product Catalog:
Products (10)
10 Results for "shunt" in MCE Product Catalog:
2
2 Cited Publications
Synonyms: BMS-986177; JNJ-70033093
Target:
Research Areas:
Milvexian is an orally bioavailable, small-molecule, reversible, direct antagonists of factor Xia, with the Ki of 0.11, 0.38, 0.64, 490, 350 nM for human, rabbit, dog, rat, mouse, respectively. Milvexian shows anti-thrombosis activity in vitro and in vivo, and can be used for thrombus study .
2
2 Cited Publications
Synonyms: IPI 1040 sodium; TBC11251 sodium
Target:
Research Areas:
Sitaxsentan sodium (IPI 1040 sodium; TBC11251 sodium) is a potent, selective and orally active endothelin A receptor (ETA) antagonist with an IC50 of 1.4 nM and a Ki of 0.43 nM. Sitaxsentan sodium exhibits an IC50 for the ETB receptor of as high as 9800 nM. Sitaxsentan sodium is metabolized by CYP2C9 and CYP3A4, normalizes shunt-induced endothelial abnormalities, restores BMPR signaling, and suppresses pulmonary vascular remodeling and hemodynamic deterioration. Sitaxsentan sodium can be applied in the research of pulmonary arterial hypertension and portopulmonary hypertension .
2
Target:
Research Areas:
Sitaxsentan (IPI 1040 sodium; TBC11251 sodium) is a potent, selective and orally active endothelin A receptor (ETA) antagonist with an IC50 of 1.4 nM and a Ki of 0.43 nM. Sitaxsentan exhibits an IC50 for the ETB receptor of as high as 9800 nM. Sitaxsentan is metabolized by CYP2C9 and CYP3A4, normalizes shunt-induced endothelial abnormalities, restores BMPR signaling, and suppresses pulmonary vascular remodeling and hemodynamic deterioration. Sitaxsentan can be applied in the research of pulmonary arterial hypertension and portopulmonary hypertension .
Target:
Research Areas:
BAY 73-1449 is a selective antagonist of prostacyclin receptor (IP), with high potency (IC50 of less than 0.1 nM) in cAMP assays in Human HEL cells and rat DRG. BAY 73-1449 can be used in the research of lowering blood pressure .
Cat. No.: HY-175735
CAS No.: 2563884-39-7
Target:
Research Areas:
Factor XI-IN-2 is a Factor XI activation inhibitor with an IC50 of 20 nM. Factor XI-IN-2 does not directly inhibit the enzymatic activity of FXIa, but specifically binds to the FXI enzyme precursor and allosterically inhibits the process by which it is activated by FXIIa. Factor XI-IN-2 inhibits thrombosis in the rabbit arteriovenous (AV) shunt thrombosis model. Factor XI-IN-2 can be used for the study of antithrombus .
Cat. No.: HY-125856A
CAS No.: 1802426-00-1
Synonyms: BMS-986177 TFA; JNJ-70033093 TFA
Target:
Research Areas:
Milvexian TFA (BMS-986177 TFA) is a factor XIa inhibitor with biological activity to prevent venous thromboembolism. Milvexian TFA was effective in reducing the occurrence of venous thromboembolism in patients undergoing knee replacement surgery. Milvexian TFA has good selectivity and shows significant inhibitory effects on plasma kallikrein and trypsin. Milvexian TFA has a bioavailability of 32%, which means it has a high absorption rate in the body. Milvexian TFA showed a relatively low risk of bleeding in clinical trials .
Cat. No.: HY-11103R
CAS No.: 210421-74-2
Synonyms: IPI 1040 sodium (Standard); TBC11251 sodium (Standard)
Research Areas:
Sitaxsentan (sodium) (Standard) is the analytical standard of Sitaxsentan sodium (IPI 1040 sodium; TBC11251 sodium) (HY-11103). This product is intended for research and analytical applications. Sitaxsentan sodium is a potent, selective and orally active endothelin A receptor (ETA) antagonist with an IC50 of 1.4 nM and a Ki of 0.43 nM. Sitaxsentan sodium exhibits an IC50 for the ETB receptor of as high as 9800 nM. Sitaxsentan sodium is metabolized by CYP2C9 and CYP3A4, normalizes shunt-induced endothelial abnormalities, restores BMPR signaling, and suppresses pulmonary vascular remodeling and hemodynamic deterioration. Sitaxsentan sodium can be applied in the research of pulmonary arterial hypertension and portopulmonary hypertension .
Cat. No.: HY-76520S
Synonyms: IPI 1040-13C6 ; TBC-11251-13C6
Cat. No.: HY-106830
CAS No.: 94386-65-9
Target:
Research Areas:
Pelrinone is an orally active cardiotonic agent and PDE III inhibitor with an IC50 of 36 μM. Pelrinone elevates intracellular cAMP levels. The action of Pelrinone is independent of β-adrenergic receptors, and it does not inhibit Na +/K +-ATPase. Pelrinone exerts positive inotropic and vasodilatory effects. Pelrinone inhibits platelet aggregation, reduces thrombus formation, and exerts weak anticoagulant activity without altering hematocrit or circulating platelet counts. Pelrinone can be used in research related to congestive heart failure and coronary thrombosis .
Cat. No.: HY-181771
IDD-AN-A1 is a potent Mycobacterium tuberculosis (Mtb) isocitrate lyase (ICL) inhibitor with an IC50 of 7 μg/mL. IDD-AN-A1 shows additive and synergistic activity with anti-tuberculosis agents. , respectively.IDD-AN-A1 exhibits potent anti-tuberculosis activity. IDD-AN-A1 can be used for the research of tuberculosis .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
